MAIA Biotechnology Missed Consensus Estimates

MAIA Biotechnology (MAIA) reported a loss of $0.13 per share on revenue of $0.00 million for the second quarter ended June 2026. The consensus estimate was a loss of $0.11 per share on revenue of $66.27 million. The company missed consensus estimates by 18.18%.

MAIA Biotechnology Inc. is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. The Company's lead program is THIO, a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of patients with telomerase-positive cancers. MAIA Biotechnology Inc. is based in CHICAGO.